HCW Biologics Inc HCWB
News
HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer
HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41st Annual Meeting
HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
HCW Biologics Announces Pricing of $1.5 Million Private Placement
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
